M&A - Neuronetics, Inc.

Form Type: 10-Q

Filing Date: 2025-05-06

Corporate Action: Acquisition

Type: Update

Accession Number: 000155837025006384

Filing Summary: Neuronetics, Inc. reports increased financial performance for the quarter ending March 31, 2025, with revenues of $31.975 million compared to $17.417 million in the same period of 2024. The cost of revenues also grew, reflecting the expansion of operations. The company incurred a loss from operations amounting to $11.014 million, higher than the previous year’s $6.859 million loss. There was a notable increase in common stock outstanding, totaling 65,820,344 shares as of May 1, 2025. A key highlight includes the acquisition of Greenbrook TMS Inc., finalized on December 9, 2024, which now allows Neuronetics to manage a network of outpatient mental health service centers specializing in TMS therapy and related treatments. The company continues to face liquidity challenges, reporting an accumulated deficit of $432.464 million. Neuronetics successfully completed a secondary public offering on February 10, 2025, raising $18.9 million in net proceeds.

Form Type: 424B5

Filing Date: 2025-02-10

Corporate Action: Acquisition

Type: New

Accession Number: 000119312525022824

Filing Summary: Neuronetics, Inc. has filed a prospectus supplement for the offering of 8,000,000 shares of common stock, listing them on The Nasdaq Global Market under the symbol 'STIM'. The public offering price is set at $2.25 per share, totaling approximately $18 million, with underwriting discounts amounting to $1.08 million. The document also details the company’s recent acquisition of Greenbrook TMS Inc., effective December 9, 2024, making it a wholly-owned subsidiary. This acquisition will allow Neuronetics to enhance its treatment offerings for mental health conditions through Greenbrook’s extensive network of treatment centers. The company’s NeuroStar Advanced Therapy system, which is a noninvasive treatment for major depressive disorder (MDD), is emphasized as a significant component of their operational model, supported by clinical data and practice management resources. The aim is to deliver innovative treatments for neurohealth conditions, leveraging the integrated practices of both companies to address mental health disorders more effectively.

Form Type: 424B5

Filing Date: 2025-02-06

Corporate Action: Acquisition

Type: New

Accession Number: 000119312525021888

Filing Summary: Neuronetics, Inc. is offering shares of its common stock, currently trading on The Nasdaq Global Market under the symbol 'STIM'. The last reported sale price was $3.27 per share. Neuronetics, a smaller reporting company, has filed a preliminary prospectus supplement detailing a public offering, which includes an agreement with Greenbrook TMS Inc., acquired as of December 9, 2024. Greenbrook is recognized as a leading provider of mental health services specializing in NeuroStar Advanced Therapy for major depressive disorder (MDD). The combination with Greenbrook allows Neuronetics to operate 95 treatment centers across the U.S., thus enhancing access to non-invasive therapies for patients. The prospectus provides risks associated with the offering, including potential dilution of shares, uncertainties in achieving profitability, and challenges in the integration process with Greenbrook. The document emphasizes the importance of understanding risk factors for potential investors, particularly regarding regulatory challenges and dependency on customer relationships.

Form Type: 8-K/A

Filing Date: 2025-02-06

Corporate Action: Acquisition

Type: Update

Accession Number: 000119312525021800

Filing Summary: Neuronetics, Inc. announced the filing of Amendment No. 1 to Form 8-K to update information regarding its acquisition of Greenbrook TMS Inc. This acquisition was initially disclosed on August 11, 2024, and became effective on December 9, 2024. The amendment includes historical financial statements of Greenbrook for the years ended December 31, 2022, and December 31, 2023, along with unaudited financial statements for nine months ended November 30, 2024. Additionally, the amendment provides unaudited pro forma financial information post-acquisition, reflecting adjustments related to the integration of Greenbrook into Neuronetics' financials.